Search results for "rheumatology"

showing 10 items of 851 documents

Aerobic exercise for axial spondyloarthritis - its effects on disease activity and function as compared to standard physiotherapy: A systematic revie…

2019

Aim To evaluate the impact of an aerobic fitness program on disease activity, defined by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and on C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and the Bath Ankylosing Spondylitis Functional Index (BASFI) in case of axial spondyloarthritis. Methods A systematic review of the literature, following the Prisma recommendations, was performed by two reviewers on the PubMed and Embase databases. Controlled trials assessing the efficacy of aerobic exercises compared to physiotherapy on axial spondyloarthritis disease activity were included. The diagnosis of axial spondyloarthritis was meeting the New York criteria and/o…

AdultMalemedicine.medical_specialty[SDV]Life Sciences [q-bio]Severity of Illness Index03 medical and health sciences0302 clinical medicineRheumatologySpondylarthritisHeart rateHumansMedicineAerobic exerciseSpondylitis Ankylosing030212 general & internal medicineAxial spondyloarthritisBASDAIPhysical Therapy ModalitiesComputingMilieux_MISCELLANEOUS030203 arthritis & rheumatologyAnkylosing spondylitismedicine.diagnostic_testbusiness.industryRecovery of FunctionMiddle Agedmedicine.diseaseExercise Therapy3. Good healthTreatment OutcomeErythrocyte sedimentation rateMeta-analysisPhysical therapyFemalebusinessBASFIInternational Journal of Rheumatic Diseases
researchProduct

The relationship between demographic- and disease-related variables and health-related quality of life in patients with axial spondyloarthritis

2017

Background Axial spondyloarthritis (ax-SpA) is a chronic inflammatory disease of the spine causing pain, stiffness, loss in physical function, and fatigue. Therefore, the physical and psychological burden of having this chronic disease can reduce the quality of life. We aimed to explore the relationship between demographic- and disease-related variables and health-related quality of life (HRQoL) in patients with ax-SpA. Methods Demographic- and disease-related, HRQoL-related and treatment data were collected. Disease measures included the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the BAS Functional Index (BASFI), the BAS Global (BAS-G) score, the Maastricht Ankylosing Spo…

AdultMalemedicine.medical_specialtylcsh:Diseases of the musculoskeletal systemSports medicineHealth-related quality of lifeUtility measures03 medical and health sciences0302 clinical medicineRheumatologyQuality of lifeInternal medicineSpondylarthritisEpidemiologymedicineHumansOrthopedics and Sports Medicine030212 general & internal medicineAxial spondyloarthritisBASDAIExerciseAged030203 arthritis & rheumatologyAnkylosing spondylitisbusiness.industryEnthesitisMiddle Agedmedicine.diseaseRheumatologyQuality of LifePhysical therapyFemaleTargeted medicationsmedicine.symptomlcsh:RC925-935BASFIbusinessResearch Article
researchProduct

“Puffy hand syndrome”

2016

Resume La toxicomanie intraveineuse est responsable de nombreuses complications notamment cutanees et infectieuses. Il existe un syndrome rarement observe en rhumatologie se traduisant par des « grosses mains » : le puffy hand syndrome. Nous en rapportons deux cas rencontres en consultation de rhumatologie chez deux patients toxicomanes. Il s’agit d’un œdeme des mains, bilateral, indolore, ne prenant pas le godet, survenant chez un de nos patients pendant l’intoxication par heroine, et chez l’autre 2 ans apres avoir arrete ses injections. Chez nos deux patients les bilans complementaires (biologiques, radiologiques, echographiques) etaient sans particularite, ce qui a permis dans le context…

AdultMalemedicine.medical_specialtymedia_common.quotation_subjectContext (language use)Physical examinationSeverity of Illness IndexSampling Studies030218 nuclear medicine & medical imagingLymphatic System030207 dermatology & venereal diseases03 medical and health sciencesRare Diseases0302 clinical medicineRheumatologyInternal medicineEdemaSeverity of illnessmedicineHumansLymphedema030212 general & internal medicinePhysical Examinationmedia_commonmedicine.diagnostic_testHeroin Dependencebusiness.industryAddictionSyndromeHandmedicine.diseaseDermatologyRheumatologySurgeryLymphedemaEtiologyFemalemedicine.symptombusinessJoint Bone Spine
researchProduct

Efficacy and Safety of Subcutaneous Belimumab in Anti–Double-Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus

2018

Objective: To investigate the efficacy and safety of belimumab, a human immunoglobulin monoclonal antibody against B lymphocyte stimulator, in a subset of patients with systemic lupus erythematosus (SLE) who were hypocomplementemic (C3 <90 mg/dl and/or C4 <10 mg/dl) and anti–double-stranded DNA (anti-dsDNA) positive (≥30 IU/ml) at baseline. Methods: In this phase III, double-blind, placebo-controlled study (BEL112341; ClinicalTrials.gov identifier: NCT01484496), patients with moderate to severe SLE (Safety of Estrogens in Lupus Erythematosus National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index [SELENA–SLEDAI] score ≥8) were randomized (2:1) to receive weekl…

AdultMalemedicine.medical_specialtymedicine.drug_classInjections SubcutaneousPopulationImmunologyPlaceboAntibodies Monoclonal HumanizedGastroenterologySystemic Lupus ErythematosusSeverity of Illness Index03 medical and health sciences0302 clinical medicineDouble-Blind MethodRheumatologyInternal medicinemedicineHumansLupus Erythematosus SystemicImmunology and Allergy030212 general & internal medicineeducationAdverse effectskin and connective tissue diseases030203 arthritis & rheumatologyeducation.field_of_studyLupus erythematosusIntention-to-treat analysisbusiness.industryComplement C3DNAmedicine.diseaseBelimumabRheumatologyIntention to Treat AnalysisTreatment OutcomeAntibodies AntinuclearImmunology and Allergy; Rheumatology; ImmunologyCorticosteroidOriginal ArticleFemalebusinessmedicine.drug
researchProduct

Macrophage Activation Syndrome in Patients Affected by Adult-onset Still Disease: Analysis of Survival Rates and Predictive Factors in the Gruppo Ita…

2018

Objective.Macrophage activation syndrome (MAS) is a reactive form of hemophagocytic lymphohistiocytosis, which can complicate adult-onset Still disease (AOSD). We investigated AOSD clinical features at the time of diagnosis, to assess predictors of MAS occurrence. Further, we analyzed the outcomes of patients with AOSD who experience MAS.Methods.Patients with AOSD admitted to any Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale center were retrospectively analyzed for features typical of AOSD, MAS occurrence, and their survival rate.Results.Of 119 patients with AOSD, 17 experienced MAS (12 at admission and 5 during followup). Twelve patients with MAS at first admission diff…

AdultMalemusculoskeletal diseases0301 basic medicineAdult onset still diseasemedicine.medical_specialtyAbdominal painMultivariate analysisSurvivalImmunologyStill DiseaseComorbidityGastroenterology03 medical and health sciences0302 clinical medicineRheumatologyInternal medicinePrevalencemedicineHumansImmunology and AllergySurvival rateRetrospective Studies030203 arthritis & rheumatologyFerritinHemophagocytic lymphohistiocytosisbiologybusiness.industryIncidencefungiMiddle AgedHyperferritinemic syndromemedicine.diseaseSurvival RateFerritin030104 developmental biologyMacrophage activation syndromeMacrophage activation syndromeFerritinsCohortbiology.proteinAdult onset still disease; Ferritin; Hyperferritinemic syndrome; Macrophage activation syndrome; Survival; Rheumatology; Immunology and Allergy; ImmunologyFemalemedicine.symptombusinessStill's Disease Adult-OnsetThe Journal of Rheumatology
researchProduct

Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 case…

2016

Macrophage activation syndrome (MAS) is a rare, life-threatening disease in which early diagnosis and aggressive therapeutic strategy may improve the outcome. Due to its rarity, epidemiologic data are still lacking. Hyperferritinemia is frequently associated with MAS and might modulate the cytokine storm, which is involved in the development of multiple organ failure. In this paper, we investigated clinical data, treatments, and outcome of a homogeneous cohort of 41 adult MAS patients, complicating autoimmune rheumatic diseases. MAS-related death occurred in 17 patients (42.5%) during the follow-up, and older age and increased serum ferritin levels, at the time of diagnosis, were significan…

AdultMalemusculoskeletal diseases0301 basic medicinemedicine.medical_specialtyImmunologyAdult onset Still's disease; Hyperferritinemic syndrome; Macrophage activation syndrome; Adult; Ambulatory Care Facilities; Autoimmune Diseases; Female; Humans; Immunosuppressive Agents; Macrophage Activation Syndrome; Male; Middle Aged; Prognosis; Retrospective Studies; Treatment Outcome; Immunology and Allergy; ImmunologyDiseaseAmbulatory Care FacilitiesAutoimmune Diseases03 medical and health sciences0302 clinical medicineAdult onset Still's diseaseInternal medicineHumansImmunology and AllergyMedicineRetrospective Studies030203 arthritis & rheumatologyAutoimmune diseaseAdult patientsbusiness.industryMortality ratefungiRetrospective cohort studyMiddle AgedPrognosisHyperferritinemic syndromemedicine.diseasebody regionsSettore MED/16 - ReumatologiaTreatment Outcome030104 developmental biologyMacrophage activation syndromeMacrophage activation syndromeCohortImmunologyFemalelipids (amino acids peptides and proteins)businessCytokine stormImmunosuppressive Agentshormones hormone substitutes and hormone antagonistsAutoimmunity Reviews
researchProduct

HLA-B27-derived peptides as autoantigens for T lymphocytes in ankylosing spondylitis

1997

Objective.To study whether peptides derived from the HLA-B27 molecule sequence can stimulate peripheral blood T lymphocytes (PBL) from patients with HLA-B27-associated spondylarthropathies. Methods.PBL from 55 HLA-B27+ patients with ankylosing spondylitis (AS), 28 HLA-B27+ patients with other spondylarthropathies, 7 rheumatoid arthritis patients, and 30 HLA-B27+ and 22 HLA-B27- healthy controls were tested in lymphocyte proliferation assays with 4 synthetic peptides derived from the HLA-B*2705 molecule. Results. A 13-mer peptide (B27PA) induced significant proliferative responses in 17 of the 55 AS patients (stimulation index [SI] 2.5–17.5), as well as in 3 of the HLA-B27+ healthy controls …

AdultMalemusculoskeletal diseasesAdolescentT-LymphocytesT cellImmunologyEnzyme-Linked Immunosorbent AssayLymphocyte proliferationLymphocyte ActivationMajor histocompatibility complexAutoantigensCell LineInterferon-gammaRheumatologyAntigenHumansImmunology and AllergyMedicineSpondylitis AnkylosingPharmacology (medical)SpondylarthropathiesHLA-B27 AntigenAgedHLA-B27biologybusiness.industryT-cell receptorReceptors Antigen T-Cell gamma-deltaT lymphocyteMiddle AgedFlow CytometryPhenotypemedicine.anatomical_structureImmunologybiology.proteinFemalePeptidesbusinessArthritis &amp; Rheumatism
researchProduct

IL 10.G microsatellites mark promoter haplotypes associated with protection against the development of reactive arthritis in Finnish patients.

2001

Objective To investigate the association of microsatellites and single-nucleotide promoter polymorphisms (SNPs) in the gene for the cytokine interleukin-10 (IL-10) with susceptibility to and outcome of reactive arthritis (ReA). Methods From genomic DNA, IL-10 microsatellites G and R and IL-10 promoter polymorphisms at positions −1087 and −524 were typed by polymerase chain reaction, automated fragment length analysis, and restriction fragment digestion in 85 Finnish patients with ReA and 62 HLA–B27–positive Finnish controls. ReA patients had been followed up for 20 years. Genotypes and haplotypes of IL-10 were correlated with distinct features of the disease course, such as triggering agent…

AdultMalemusculoskeletal diseasesGenetic LinkageImmunologySingle-nucleotide polymorphismArthritis ReactivePolymorphism Single NucleotideRestriction fragmentRheumatologyProhibitinsGenotypeHumansImmunology and AllergyPharmacology (medical)AllelePromoter Regions GeneticAllele frequencyFinlandGeneticsbiologyreactive arthritis IL-10 microsatellites polymorphismHaplotypeMiddle AgedInterleukin-10HaplotypesImmunologybiology.proteinMicrosatelliteFemaleRestriction fragment length polymorphismFollow-Up StudiesMicrosatellite Repeats
researchProduct

No primary association between LMP2 polymorphisms and extraspinal manifestations in spondyloarthropathies

1997

OBJECTIVE—To investigate the potential role of the HLA-linked LMP2 (low molecular weight protein) gene polymorphisms in conjunction with DR4 and DR7 on extraspinal disease manifestations in HLA-B27 positive patients with spondyloarthropathy.
METHODS—172 patients with spondyloarthropathy, 46 healthy, HLA-B27 positive blood donors, and 99 unrelated controls were typed for HLA-class I and II antigens. LMP2 alleles were determined by polymerase chain reaction and subsequent restriction enzyme digestion.
RESULTS—There were statistically non-significant increases of DR4 and DR7 in spondyloarthropathy subjects. However these differences did not relate to specific extraspinal manifestations. There …

AdultMalemusculoskeletal diseasesLinkage disequilibriumAdolescentSpondyloarthropathyImmunologyHLA-DR7 AntigenDiseaseGeneral Biochemistry Genetics and Molecular BiologyGenetic determinismUveitisPathogenesisRheumatologyCorrespondenceGenotypeHLA-DR4 Antigenotorhinolaryngologic diseasesmedicineHumansImmunology and AllergyAlleleskin and connective tissue diseasesHLA-B27 AntigenConcise ReportsAgedAged 80 and overPolymorphism Geneticbusiness.industryArthritisProteinsMiddle Agedmedicine.diseaseGenotype frequencyCysteine Endopeptidasesstomatognathic diseasesImmunologyFemaleSpinal DiseasesbusinessAnnals of the Rheumatic Diseases
researchProduct

Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind co…

2003

Objective: To evaluate whether early combined therapy with methotrexate (MTX) and sulfasalazine (SSZ) during the first year in early rheumatoid arthritis (RA) induces long term beneficial effects, compared with monotherapy, when the further treatment strategy is a free choice. Methods: Study design: five year multicentre prospective longitudinal trial. Participants: 146/205 patients with RA previously included in a one year prospective randomised trial comparing the effects of treatment with MTX, SSZ, or a combination of both. Criteria for inclusion: patients with early RA (⩽1 year duration). Follow up: between the end of years 1 and 5, patients were followed up and treated by their own rhe…

AdultMalemusculoskeletal diseasesmedicine.medical_specialtyConcise ReportCombination therapymedicine.medical_treatmentImmunologyArthritisSeverity of Illness IndexGeneral Biochemistry Genetics and Molecular Biologylaw.inventionArthritis RheumatoidDouble-Blind MethodRheumatologyRandomized controlled triallawSulfasalazineInternal medicinemedicineHumansImmunology and AllergyProspective StudiesDisease-modifying antirheumatic drugskin and connective tissue diseasesProspective cohort studyAgedAnalysis of Variancebusiness.industryMiddle Agedmedicine.diseaseSurgerySulfasalazineClinical trialMethotrexateTreatment OutcomeAntirheumatic AgentsRheumatoid arthritisDrug Therapy CombinationFemalebusinessFollow-Up Studiesmedicine.drugAnnals of the Rheumatic Diseases
researchProduct